Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I Mab : Cantor Fitzgerald Adjusts I-Mab PT to $95 From $90, Maintains Overweight Rating

07/13/2021 | 09:34am EST


ę MT Newswires 2021
All news about I-MAB
09:14aI-Mab Seeks Dual Listing on Hong Kong Stock Exchange
MT
08:01aI-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong ..
PR
12/06I MAB : Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlima..
PU
12/03Health Care Stocks Drifting Lower Ahead of Weekend
MT
12/03I-Mab Starts Dosing in US Mid-Stage Combination Trial of Uliledlimab with Atezolizumab ..
MT
12/03I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlim..
PR
12/03I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlim..
CI
11/12I MAB : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
11/12I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2..
PU
11/12I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Anti..
CI
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2021 87,8 M - -
Net income 2021 -175 M - -
Net cash 2021 589 M - -
P/E ratio 2021 -28,6x
Yield 2021 -
Capitalization 3 798 M 3 798 M -
EV / Sales 2021 36,6x
EV / Sales 2022 18,8x
Nbr of Employees 228
Free-Float 98,2%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 49,35 $
Average target price 96,47 $
Spread / Average Target 95,5%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
John Long Chief Financial Officer
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB4.67%3 798
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321